Maintenance DFMO Increases Survival in High Risk Neuroblastoma
High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (...
Saved in:
| Published in | Scientific reports Vol. 8; no. 1; pp. 14445 - 9 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
27.09.2018
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m
2
twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB. |
|---|---|
| AbstractList | High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m
2
twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB. High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m2 twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB. High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB. High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m2 twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB.High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m2 twice daily). Event free survival (EFS) and overall survival (OS) were determined on an intention-to-treat (ITT) basis. 101 subjects enrolled on Stratum 1 and 100 were eligible for ITT analysis; two-year EFS was 84% (±4%) and OS 97% (±2%). 39 subjects enrolled on Stratum 2, with a two-year EFS of 54% (±8%) and OS 84% (±6%). DFMO was well tolerated. The median survival time is not yet defined for either stratum. DFMO maintenance therapy for HRNB in remission is safe and associated with high EFS and OS. Targeting ODC represents a novel therapeutic mechanism that may provide a new strategy for preventing relapse in children with HRNB. |
| ArticleNumber | 14445 |
| Author | Sholler, Giselle L. Saulnier Oesterheld, Javier Neville, Kathleen Bergendahl, Genevieve Eslin, Don Zage, Peter Ferguson, William Sencer, Susan Rich, Maria Foley, Jessica Pankiewicz, Debra Brown, Valerie Wada, Randal K. Mitchell, Deanna Roberts, William Parikh, Nehal S. Kraveka, Jacqueline M. Junewick, Joseph Rawwas, Jawhar Quinn, Monique Bond, Jeffrey P. Eshun, Francis |
| Author_xml | – sequence: 1 givenname: Giselle L. Saulnier surname: Sholler fullname: Sholler, Giselle L. Saulnier email: giselle.sholler@helendevoschildrens.org organization: Helen DeVos Children’s Hospital at Spectrum Health, Michigan State University College of Human Medicine – sequence: 2 givenname: William surname: Ferguson fullname: Ferguson, William organization: Saint Louis University School of Medicine – sequence: 3 givenname: Genevieve surname: Bergendahl fullname: Bergendahl, Genevieve organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 4 givenname: Jeffrey P. surname: Bond fullname: Bond, Jeffrey P. organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 5 givenname: Kathleen surname: Neville fullname: Neville, Kathleen organization: Arkansas Children’s Hospital – sequence: 6 givenname: Don surname: Eslin fullname: Eslin, Don organization: Arnold Palmer Hospital for Children – sequence: 7 givenname: Valerie surname: Brown fullname: Brown, Valerie organization: Penn State Health Children’s Hospital at the Penn State Milton S. Hershey Medical Center – sequence: 8 givenname: William surname: Roberts fullname: Roberts, William organization: Rady Children’s Hospital San Diego and UC San Diego School of Medicine – sequence: 9 givenname: Randal K. surname: Wada fullname: Wada, Randal K. organization: Kapiolani Medical Center for Women and Children – sequence: 10 givenname: Javier surname: Oesterheld fullname: Oesterheld, Javier organization: Levine Children’s Hospital – sequence: 11 givenname: Deanna surname: Mitchell fullname: Mitchell, Deanna organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 12 givenname: Jessica surname: Foley fullname: Foley, Jessica organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 13 givenname: Nehal S. surname: Parikh fullname: Parikh, Nehal S. organization: Connecticut Children’s Medical Center – sequence: 14 givenname: Francis surname: Eshun fullname: Eshun, Francis organization: Phoenix Children’s Hospital – sequence: 15 givenname: Peter surname: Zage fullname: Zage, Peter organization: Rady Children’s Hospital San Diego and UC San Diego School of Medicine – sequence: 16 givenname: Jawhar surname: Rawwas fullname: Rawwas, Jawhar organization: Children’s Hospitals and Clinics of Minnesota – sequence: 17 givenname: Susan surname: Sencer fullname: Sencer, Susan organization: Children’s Hospitals and Clinics of Minnesota – sequence: 18 givenname: Debra surname: Pankiewicz fullname: Pankiewicz, Debra organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 19 givenname: Monique surname: Quinn fullname: Quinn, Monique organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 20 givenname: Maria surname: Rich fullname: Rich, Maria organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 21 givenname: Joseph surname: Junewick fullname: Junewick, Joseph organization: Helen DeVos Children’s Hospital at Spectrum Health – sequence: 22 givenname: Jacqueline M. surname: Kraveka fullname: Kraveka, Jacqueline M. organization: Medical University of South Carolina |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30262852$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1PFTEUhhuDEUT-gAsziRs3o-3p52xIDIqQgCR-rJtO59xLcW6L7cwl_nt7vYjIgm7atM97znv6Pic7MUUk5CWjbxnl5l0RTHampcy0HJTs2psnZA-okC1wgJ17511yUMoVrUtCJ1j3jOxyCgqMhD1yeO5CnDC66LH5cHx-0ZxGn9EVLM3XOa_D2o1NiM1JWF42X0L50XzGOad-dGVKK_eCPF24seDB7b5Pvh9__HZ00p5dfDo9en_WeqHF1CqO1YgSQnvWSw0LrQXTCyZx6LVy2gy9UXIwzCPvjRzogIgOBsoRuaqX--RwW_d67lc4eIxTdqO9zmHl8i-bXLD_v8RwaZdpbRVTVHBRC7y5LZDTzxnLZFeheBxHFzHNxQJjQlOg0FX09QP0Ks051vE2FAfRUdCVenXf0Z2Vv19bAdgCPqdSMi7uEEbtJkK7jdDWCO2fCO1NFZkHIh8mN4W0mSqMj0v5Vlpqn7jE_M_2I6rfnhqv-Q |
| CitedBy_id | crossref_primary_10_3390_medsci9020028 crossref_primary_10_1042_BCJ20210647 crossref_primary_10_1016_j_xcrm_2023_101261 crossref_primary_10_3390_jpm11050395 crossref_primary_10_1002_jez_2351 crossref_primary_10_1080_1061186X_2022_2036164 crossref_primary_10_1002_advs_202204038 crossref_primary_10_1200_JCO_24_00546 crossref_primary_10_1200_PO_24_00491 crossref_primary_10_1002_path_6330 crossref_primary_10_1016_j_semcancer_2022_04_006 crossref_primary_10_1111_cpr_12891 crossref_primary_10_1016_j_xcrm_2022_100720 crossref_primary_10_1002_ijc_33044 crossref_primary_10_3389_fphar_2020_00277 crossref_primary_10_1016_j_ejca_2020_05_010 crossref_primary_10_3389_fonc_2020_623679 crossref_primary_10_3389_fonc_2023_1212604 crossref_primary_10_1016_j_ejca_2023_113291 crossref_primary_10_1111_dmcn_15687 crossref_primary_10_3390_cancers13143531 crossref_primary_10_3390_cancers14010139 crossref_primary_10_3390_biomedicines11102703 crossref_primary_10_1002_cam4_7207 crossref_primary_10_1021_acs_jnatprod_0c00613 crossref_primary_10_7759_cureus_37680 crossref_primary_10_1038_s41568_022_00473_2 crossref_primary_10_1016_j_phrs_2020_104943 crossref_primary_10_1002_advs_202005047 crossref_primary_10_1074_jbc_TM118_003336 crossref_primary_10_1186_s13065_024_01262_8 crossref_primary_10_1016_j_tips_2024_04_005 crossref_primary_10_1042_BCJ20190294 crossref_primary_10_1128_mBio_02616_20 crossref_primary_10_1177_12034754241302818 crossref_primary_10_1021_acsnano_1c04031 crossref_primary_10_1038_s41568_019_0187_8 crossref_primary_10_3390_molecules25051135 crossref_primary_10_3390_ijms222413175 crossref_primary_10_1021_acsabm_2c00309 crossref_primary_10_1007_s00280_020_04201_1 crossref_primary_10_3390_cells11050896 crossref_primary_10_1002_lary_30231 crossref_primary_10_1038_s41571_022_00643_z crossref_primary_10_1021_acs_joc_4c00702 crossref_primary_10_1186_s12645_023_00186_7 crossref_primary_10_1002_cnr2_1616 crossref_primary_10_3390_ijms222312883 crossref_primary_10_1002_ijc_33140 crossref_primary_10_1200_JCO_22_02875 crossref_primary_10_1038_s41388_021_01862_x crossref_primary_10_1007_s11864_021_00898_1 crossref_primary_10_1097_CJI_0000000000000379 crossref_primary_10_1007_s00018_019_03196_0 crossref_primary_10_3724_abbs_2025030 crossref_primary_10_1038_s41598_022_16007_7 crossref_primary_10_1371_journal_pone_0236115 crossref_primary_10_1080_14756366_2022_2150186 crossref_primary_10_1097_MOP_0000000000000853 crossref_primary_10_1038_s41417_021_00386_6 crossref_primary_10_1042_BST20221035 crossref_primary_10_1097_MD_0000000000040662 crossref_primary_10_1016_j_prro_2023_12_008 crossref_primary_10_1097_CCO_0000000000001134 crossref_primary_10_1016_j_canlet_2024_217393 crossref_primary_10_1371_journal_ppat_1010503 crossref_primary_10_1016_j_celrep_2024_115123 crossref_primary_10_3390_ijms25020996 |
| Cites_doi | 10.1002/jcb.22094 10.1200/JCO.2008.16.6785 10.1158/1078-0432.CCR-13-1012 10.1007/BF00203544 10.1200/JCO.2011.41.3807 10.1056/NEJMoa0911123 10.1002/cncr.30934 10.1038/bmt.2013.218 10.1007/s10689-009-9237-9 10.1093/jnci/djp230 10.1158/0008-5472.CAN-08-2968 10.1016/S0140-6736(07)60983-0 10.1016/S1470-2045(05)70291-6 10.1002/cncr.23507 10.1097/01.ju.0000108384.74718.73 10.1002/ijc.28139 10.3892/ijo.2013.1835 10.1371/journal.pone.0127246 10.3389/fgene.2017.00031 10.1016/j.pcl.2014.09.015 10.1158/1940-6207.CAPR-09-0096 10.1200/JCO.2014.59.4648 10.1200/JCO.2004.08.143 10.18632/oncotarget.2768 10.1158/0008-5472.CAN-07-6866 10.1158/1078-0432.CCR-09-0592 10.1093/jnci/86.15.1122 10.1158/0008-5472.CAN-08-1865 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2018 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2018 – notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.1038/s41598-018-32659-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | PMC6160434 30262852 10_1038_s41598_018_32659_w |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: The funding sources include the Beat NB Foundation, Meryl and Charles Witmer Foundation, Lillies Friends Foundation, Dick and Betsy DeVos Family Foundation, Owen Moscone Foundation, Brooke’s Blossoming Hope for Childhood Cancer Foundation, Ethan’s Rodeo, and the Jesse Heikkila Foundation. The funding organizations did not have a role in the research or writing of the manuscript. – fundername: ; |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS EJD ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IPNFZ KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT NPM 7XB 8FK AARCD K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c474t-63e3226447c1b572f77417f15edb76a78db865d81ce3b85d0deeea2d03ee36ce3 |
| IEDL.DBID | M48 |
| ISSN | 2045-2322 |
| IngestDate | Thu Aug 21 18:20:29 EDT 2025 Thu Jul 10 18:53:42 EDT 2025 Wed Aug 13 04:04:53 EDT 2025 Wed Feb 19 02:42:38 EST 2025 Tue Jul 01 00:58:08 EDT 2025 Thu Apr 24 23:10:32 EDT 2025 Fri Feb 21 02:38:16 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Oral DFMO DFMO Dose High-risk Neuroblastoma (HRNB) Primary Refractory Disease Difluoromethylornithine (DFMO) |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-63e3226447c1b572f77417f15edb76a78db865d81ce3b85d0deeea2d03ee36ce3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-018-32659-w |
| PMID | 30262852 |
| PQID | 2113249027 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6160434 proquest_miscellaneous_2114702029 proquest_journals_2113249027 pubmed_primary_30262852 crossref_primary_10_1038_s41598_018_32659_w crossref_citationtrail_10_1038_s41598_018_32659_w springer_journals_10_1038_s41598_018_32659_w |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-09-27 |
| PublicationDateYYYYMMDD | 2018-09-27 |
| PublicationDate_xml | – month: 09 year: 2018 text: 2018-09-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2018 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Meyskens (CR25) 1994; 86 Berthold (CR4) 2005; 6 Cheung (CR6) 2012; 30 Cohen (CR32) 2014; 49 Laverdiere (CR31) 2009; 101 Hogarty (CR14) 2008; 68 Brown (CR22) 2009; 8 CR17 Wagner, Danks (CR8) 2009; 107 Bailey (CR26) 2010; 3 Griffin (CR33) 1987; 5 London (CR10) 2017; 123 Irwin, Park (CR1) 2015; 62 Maris, Hogarty, Bagatell, Cohn (CR20) 2007; 369 Lozier (CR16) 2015; 6 Cohn (CR19) 2009; 27 Koomoa (CR29) 2013; 42 Rounbehler (CR28) 2009; 69 Balzeau, Menezes, Cao, Hagan (CR30) 2017; 8 Simon (CR3) 2004; 22 Yu (CR5) 2010; 363 CR7 Pinto (CR2) 2015; 33 CR24 Samal (CR12) 2013; 133 Zell (CR23) 2009; 15 Visvanathan (CR21) 2004; 171 Saulnier Sholler (CR18) 2015; 10 Meyskens, Gerner (CR11) 1999; 5 Hixson (CR13) 1993; 2 Santana, Furman, McGregor, Billups (CR9) 2008; 112 Koomoa, Yco, Borsics, Wallick, Bachmann (CR15) 2008; 68 Kushner (CR27) 2014; 20 JA Zell (32659_CR23) 2009; 15 WB London (32659_CR10) 2017; 123 NR Pinto (32659_CR2) 2015; 33 MD Hogarty (32659_CR14) 2008; 68 SL Cohn (32659_CR19) 2009; 27 K Visvanathan (32659_CR21) 2004; 171 FL Meyskens Jr. (32659_CR25) 1994; 86 HH Bailey (32659_CR26) 2010; 3 T Simon (32659_CR3) 2004; 22 DL Koomoa (32659_CR15) 2008; 68 C Laverdiere (32659_CR31) 2009; 101 32659_CR24 J Balzeau (32659_CR30) 2017; 8 CA Griffin (32659_CR33) 1987; 5 MS Irwin (32659_CR1) 2015; 62 LE Cohen (32659_CR32) 2014; 49 VM Santana (32659_CR9) 2008; 112 JM Maris (32659_CR20) 2007; 369 F Berthold (32659_CR4) 2005; 6 AL Yu (32659_CR5) 2010; 363 GL Saulnier Sholler (32659_CR18) 2015; 10 32659_CR7 BH Kushner (32659_CR27) 2014; 20 FL Meyskens Jr. (32659_CR11) 1999; 5 RJ Rounbehler (32659_CR28) 2009; 69 NK Cheung (32659_CR6) 2012; 30 LJ Hixson (32659_CR13) 1993; 2 AM Lozier (32659_CR16) 2015; 6 I Brown (32659_CR22) 2009; 8 K Samal (32659_CR12) 2013; 133 32659_CR17 DL Koomoa (32659_CR29) 2013; 42 LM Wagner (32659_CR8) 2009; 107 |
| References_xml | – volume: 107 start-page: 46 year: 2009 end-page: 57 ident: CR8 article-title: New therapeutic targets for the treatment of high-risk neuroblastoma publication-title: J Cell Biochem doi: 10.1002/jcb.22094 – volume: 27 start-page: 289 year: 2009 end-page: 297 ident: CR19 article-title: TheInternational Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2008.16.6785 – volume: 20 start-page: 1375 year: 2014 end-page: 1382 ident: CR27 article-title: Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1012 – volume: 5 start-page: 177 year: 1987 end-page: 186 ident: CR33 article-title: Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine publication-title: Investigational new drugs doi: 10.1007/BF00203544 – volume: 30 start-page: 3264 year: 2012 end-page: 3270 ident: CR6 article-title: Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2011.41.3807 – volume: 363 start-page: 1324 year: 2010 end-page: 1334 ident: CR5 article-title: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma publication-title: The New England journal of medicine doi: 10.1056/NEJMoa0911123 – volume: 5 start-page: 945 year: 1999 end-page: 951 ident: CR11 article-title: Development of difluoromethylornithine (DFMO) as a chemoprevention agent publication-title: Clin Cancer Res – volume: 123 start-page: 4914 year: 2017 end-page: 4923 ident: CR10 article-title: Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials publication-title: Cancer doi: 10.1002/cncr.30934 – volume: 49 start-page: 502 year: 2014 end-page: 508 ident: CR32 article-title: Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems publication-title: Bone marrow transplantation doi: 10.1038/bmt.2013.218 – volume: 8 start-page: 307 year: 2009 end-page: 311 ident: CR22 article-title: Genetic polymorphism in ornithine decarboxylase and risk of breast cancer publication-title: Fam Cancer doi: 10.1007/s10689-009-9237-9 – volume: 101 start-page: 1131 year: 2009 end-page: 1140 ident: CR31 article-title: Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp230 – volume: 69 start-page: 547 year: 2009 end-page: 553 ident: CR28 article-title: Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2968 – volume: 369 start-page: 2106 year: 2007 end-page: 2120 ident: CR20 article-title: Neuroblastoma publication-title: Lancet doi: 10.1016/S0140-6736(07)60983-0 – volume: 6 start-page: 649 year: 2005 end-page: 658 ident: CR4 article-title: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70291-6 – volume: 112 start-page: 2796 year: 2008 end-page: 2801 ident: CR9 article-title: Disease control intervals in high-risk neuroblastoma publication-title: Cancer doi: 10.1002/cncr.23507 – volume: 171 start-page: 652 year: 2004 end-page: 655 ident: CR21 article-title: Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk publication-title: J Urol doi: 10.1097/01.ju.0000108384.74718.73 – volume: 133 start-page: 1323 year: 2013 end-page: 1333 ident: CR12 article-title: AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport publication-title: Int J Cancer doi: 10.1002/ijc.28139 – volume: 42 start-page: 1219 year: 2013 end-page: 1228 ident: CR29 article-title: DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma publication-title: Int J Oncol doi: 10.3892/ijo.2013.1835 – volume: 10 start-page: e0127246 year: 2015 ident: CR18 article-title: A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma publication-title: PLoS One doi: 10.1371/journal.pone.0127246 – volume: 8 start-page: 31 year: 2017 ident: CR30 article-title: The LIN28/let-7 Pathway in Cancer publication-title: Front Genet doi: 10.3389/fgene.2017.00031 – ident: CR17 – volume: 62 start-page: 225 year: 2015 end-page: 256 ident: CR1 article-title: Neuroblastoma: paradigm for precision medicine publication-title: Pediatric clinics of North America doi: 10.1016/j.pcl.2014.09.015 – volume: 3 start-page: 35 year: 2010 end-page: 47 ident: CR26 article-title: A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer publication-title: Cancer prevention research doi: 10.1158/1940-6207.CAPR-09-0096 – volume: 33 start-page: 3008 year: 2015 end-page: 3017 ident: CR2 article-title: Advances in Risk Classification and Treatment Strategies for Neuroblastoma publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2014.59.4648 – volume: 22 start-page: 3549 year: 2004 end-page: 3557 ident: CR3 article-title: Consolidation treatment with chimeric anti-GD2-antibodych14.18 in children older than 1 year with metastatic neuroblastoma publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2004.08.143 – volume: 2 start-page: 369 year: 1993 end-page: 374 ident: CR13 article-title: Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa publication-title: Cancer Epidemiol Biomarkers Prev – ident: CR7 – volume: 6 start-page: 196 year: 2015 end-page: 206 ident: CR16 article-title: Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma publication-title: Oncotarget doi: 10.18632/oncotarget.2768 – volume: 68 start-page: 9735 year: 2008 end-page: 9745 ident: CR14 article-title: ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6866 – volume: 15 start-page: 6208 year: 2009 end-page: 6216 ident: CR23 article-title: Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0592 – volume: 86 start-page: 1122 year: 1994 end-page: 1130 ident: CR25 article-title: Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps publication-title: J Natl Cancer Inst doi: 10.1093/jnci/86.15.1122 – ident: CR24 – volume: 68 start-page: 9825 year: 2008 end-page: 9831 ident: CR15 article-title: Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1865 – volume: 22 start-page: 3549 year: 2004 ident: 32659_CR3 publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2004.08.143 – volume: 20 start-page: 1375 year: 2014 ident: 32659_CR27 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1012 – volume: 6 start-page: 196 year: 2015 ident: 32659_CR16 publication-title: Oncotarget doi: 10.18632/oncotarget.2768 – volume: 5 start-page: 177 year: 1987 ident: 32659_CR33 publication-title: Investigational new drugs doi: 10.1007/BF00203544 – ident: 32659_CR24 – volume: 107 start-page: 46 year: 2009 ident: 32659_CR8 publication-title: J Cell Biochem doi: 10.1002/jcb.22094 – volume: 42 start-page: 1219 year: 2013 ident: 32659_CR29 publication-title: Int J Oncol doi: 10.3892/ijo.2013.1835 – volume: 5 start-page: 945 year: 1999 ident: 32659_CR11 publication-title: Clin Cancer Res – volume: 62 start-page: 225 year: 2015 ident: 32659_CR1 publication-title: Pediatric clinics of North America doi: 10.1016/j.pcl.2014.09.015 – volume: 2 start-page: 369 year: 1993 ident: 32659_CR13 publication-title: Cancer Epidemiol Biomarkers Prev – volume: 6 start-page: 649 year: 2005 ident: 32659_CR4 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70291-6 – volume: 27 start-page: 289 year: 2009 ident: 32659_CR19 publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2008.16.6785 – volume: 68 start-page: 9735 year: 2008 ident: 32659_CR14 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6866 – volume: 68 start-page: 9825 year: 2008 ident: 32659_CR15 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1865 – volume: 8 start-page: 31 year: 2017 ident: 32659_CR30 publication-title: Front Genet doi: 10.3389/fgene.2017.00031 – volume: 8 start-page: 307 year: 2009 ident: 32659_CR22 publication-title: Fam Cancer doi: 10.1007/s10689-009-9237-9 – volume: 33 start-page: 3008 year: 2015 ident: 32659_CR2 publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2014.59.4648 – volume: 15 start-page: 6208 year: 2009 ident: 32659_CR23 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0592 – volume: 369 start-page: 2106 year: 2007 ident: 32659_CR20 publication-title: Lancet doi: 10.1016/S0140-6736(07)60983-0 – volume: 123 start-page: 4914 year: 2017 ident: 32659_CR10 publication-title: Cancer doi: 10.1002/cncr.30934 – volume: 10 start-page: e0127246 year: 2015 ident: 32659_CR18 publication-title: PLoS One doi: 10.1371/journal.pone.0127246 – volume: 363 start-page: 1324 year: 2010 ident: 32659_CR5 publication-title: The New England journal of medicine doi: 10.1056/NEJMoa0911123 – volume: 101 start-page: 1131 year: 2009 ident: 32659_CR31 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp230 – volume: 30 start-page: 3264 year: 2012 ident: 32659_CR6 publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2011.41.3807 – volume: 69 start-page: 547 year: 2009 ident: 32659_CR28 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2968 – volume: 171 start-page: 652 year: 2004 ident: 32659_CR21 publication-title: J Urol doi: 10.1097/01.ju.0000108384.74718.73 – volume: 112 start-page: 2796 year: 2008 ident: 32659_CR9 publication-title: Cancer doi: 10.1002/cncr.23507 – ident: 32659_CR7 – volume: 3 start-page: 35 year: 2010 ident: 32659_CR26 publication-title: Cancer prevention research doi: 10.1158/1940-6207.CAPR-09-0096 – volume: 49 start-page: 502 year: 2014 ident: 32659_CR32 publication-title: Bone marrow transplantation doi: 10.1038/bmt.2013.218 – ident: 32659_CR17 – volume: 133 start-page: 1323 year: 2013 ident: 32659_CR12 publication-title: Int J Cancer doi: 10.1002/ijc.28139 – volume: 86 start-page: 1122 year: 1994 ident: 32659_CR25 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/86.15.1122 |
| SSID | ssj0000529419 |
| Score | 2.519183 |
| Snippet | High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse,... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 14445 |
| SubjectTerms | 631/67/2332 692/4028/67/2332 Cancer Children Eflornithine Humanities and Social Sciences Motivation multidisciplinary Neuroblastoma Ornithine Ornithine decarboxylase Remission Science Science (multidisciplinary) Survival |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0RPBF_LbeKRF803BN89kXj0NdDmEV1IN9K22a4KJ2T7vL4X9_M2m3x3p4r01Km5lk8pvM5DcAr3wM3pW15HktPVe1FdwJU_PGosmM6BWJRKU0_2ROTtXHhV6MB279mFa5tYnJULcrT2fkhwWVRFclelFHZ785VY2i6OpYQuMm3CLqMkrpsgs7nbFQFEuJcrwrk0t32ON-RXfKhOOIW3TJz3f3oysg82qu5D8B07QPze7B3RFAsuNB4_fhRugewO2hpOTfh_B2XhMDBNFoBPZ-Nv_M0AJQ4nno2dcN2gWcWWzZMcrvYF-W_Q-W6DkaBNHr1a_6EZzOPnx7d8LHGgncK6vW3Mgg6S6ssl402hYR4ZywUejQNtbU1rWNM7p1wgfZON3mbQihLtpchiANPnwMe92qC0-BhRLRYusjuoxaBefQ03A6FlHGslRGxQzEVlKVHwnEqY7FzyoFsqWrBulWKN0qSbc6z-D19M7ZQJ9xbe-DrQKqcSn11aXiM3g5NeMioMhG3YXVJvVRFoFvUWbwZNDX9DmJXmbhdJGB3dHk1IEItndbuuX3RLRthMmVVBm82er88rf-P4pn149iH-4UNP8osmUPYG_9ZxOeI7BZNy_S7L0A3E_0uw priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEB_OE8GX487P3odE8E2DTfPZF0FWl0NYBfXg3kraTnBRu-LucvjfO0k_ZD0VfG0Sms5Mkt90Zn4BeNIEbFzpJc-9bLjyVnAnjOe1pS0zkFckEpXS4q05v1BvLvXlHhRjLUxK2k-UlmmbHrPDnq_poInFYMJxAhy65Fc34Gakbo9WPTOz6b9KjFwpUQ71Mbl0fxi6ewZdA5bX8yN_C5Kms2d-CAcDaGQv-2kewR52d-BWf43kj7vwYuEj60OkzkD2ar54x2jVx2RzXLMPW9oLyJrYsmMxp4O9X64_s0TJURNw3qy--ntwMX_9cXbOh3sReKOs2nAjUcb6V2UbUWtbBIJwwgahsa2t8da1tTO6daJBWTvd5i0i-qLNJaI09PA-7HerDh8Cw5IQYtsEchO1QufIu3A6FEGGslRGhQzEKKmqGUjD490VX6oUvJau6qVbkXSrJN3qKoOn05hvPWXGP3ufjgqohuWzrsgrJaBXksucweOpmQw_RjN8h6tt6qMsgd2izOBBr6_pdZI8y8LpIgO7o8mpQyTV3m3plp8SubYRJldSZfBs1Pmvaf39K47_r_sJ3C6iPcbolj2F_c33LZ4RuNnUj5I1_wSegvM5 priority: 102 providerName: Springer Nature |
| Title | Maintenance DFMO Increases Survival in High Risk Neuroblastoma |
| URI | https://link.springer.com/article/10.1038/s41598-018-32659-w https://www.ncbi.nlm.nih.gov/pubmed/30262852 https://www.proquest.com/docview/2113249027 https://www.proquest.com/docview/2114702029 https://pubmed.ncbi.nlm.nih.gov/PMC6160434 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_tQ6C9IL4X2Coj8QaBOv5-AFTKqqlSB9qo1LfISRxRbUvH2mrsv-fsJJ3KNp4i-UNx7s7273L27wDe5qXLtbEs7lqWx9wqGmsqbZwpXDJL9IpooFIaHcnDMR9OxGQD2nRHjQDnd7p2Pp_U-PLsw5_f119wwn-qr4zrj3PchPxFMapjBCPCxFebsI07k_ITddTA_ZrrOzGcmubuzN1dd-AhQ78k0SJZ36pu4c_bxyj_iaWGLWrwGB412JL0amN4AhuuegoP6myT18_g88h6cgjPsOHIt8HoO8HFwZ9Jd3NyssQlA42OTCvij36Q4-n8lATmjgzx9WJ2bp_DeHDws38YN-kT4pwrvoglc8xfk-Uqp5lQSYlIj6qSCldkSlqli0xLUWiaO5ZpUXQL55xNii5zjkksfAFb1axyu0CcQSBZ5CV6k4I7rdEJ0aJMSlYawyUvI6CtpNK84Rb3KS7O0hDjZjqtBZ2ioNMg6PQqgnerPhc1s8Z_W--1CkhbI0nReUU8aNCzjuDNqhrnhw962MrNlqENV4iJExPBy1pfq9e1io5ArWly1cBzb6_XVNNfgYNbUtnljEfwvtX5zbDu_4pX9w7hNewk3gp9vEvtwdbicun2Ee4ssg5sqonqwHavNzwZ4vPrwdGPYyzty34n_ELoBCv_CyDf_fU |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VrRC8IG4CBYwET2A1vmLnARDQrra0u6DSSn0zORx1VcgWsqtV_xS_kXGuaqnoW18T5_DMePyN5wJ4mRUuM3EiaJiIjMpEM2pYlNBUo8os0CpidSml8SQaHcrPR-poDf50uTA-rLLTibWizmeZPyPf5L4luozRinp_-ov6rlHeu9q10GjEYtedLdFkq97ubCF_X3E-3D74NKJtVwGaSS3nNBJO-OxRqTOWKs0LBEBMF0y5PNVRok2emkjlhmVOpEblYe6cS3geCudEhBfxvddgXQo0ZQaw_nF78nW_P9XxfjPJ4jY7JxRms8Id0mexMUMRKamYLld3wAuw9mJ05j8u2nrnG96GWy1kJR8aGbsDa668C9ebJpZn9-DdOPE1J3zhDke2huMvBHWOD3V3Ffm2QE2EskymJfERJWR_Wp2QuiBIirB9PvuZ3IfDK6HfAxiUs9I9AuJixKd5VqCRqqQzBm0bowpeiCKOZSSLAFhHKZu1Jct954wftnadC2Mb6lqkrq2pa5cBvO6fOW0Kdlw6eqNjgG0Xb2XPRS2AF_1tXHbel5KUbraox0iNUJvHATxs-NV_TqBdy43iAegVTvYDfEnv1Tvl9Lgu7R2xKJRCBvCm4_n5b_1_Fo8vn8VzuDE6GO_ZvZ3J7hO4yb0ser-a3oDB_PfCPUVYNU-ftbJM4PtVL5-_fM0zpw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VIhAviJtAASPBE1iNr9h5AIRYVi1lCwIq7ZvJYaurQraQXa361_h1jHNVS0Xf-po4h-fyjGf8DcCzwrvCpJmgcSYKKjPNqGFJRnONJtNjVMQaKKXJfrJzID9M1XQD_vRnYUJZZW8TG0NdzouwR77NQ0t0mYZQ3XdlEZ9H4zfHv2joIBUyrX07jVZE9tzJCsO3-tXuCHn9nPPx-2_vdmjXYYAWUssFTYQT4SSp1AXLleYenSGmPVOuzHWSaVPmJlGlYYUTuVFlXDrnMl7GwjmR4EV87yW4rIViQcf0VA_7OyGDJlnandOJhdmuca0M59mYoegzqZSu1tfCMw7u2TrNf5K1zRo4vgHXO-eVvG2l7SZsuOoWXGnbWZ7chteTLKBPBAgPR0bjySeC1icUvbuafF2iTUKpJrOKhNoS8mVWH5EGGiRHB34x_5ndgYMLod5d2KzmlbsPxKXoqZaFx3BVSWcMRjlGee6FT1OZSB8B6ylliw68PPTQ-GGbJLowtqWuRerahrp2FcGL4ZnjFrrj3NFbPQNsp8a1PRW6CJ4Ot1EBQ1Ylq9x82YyRGp1unkZwr-XX8DmBES43ikeg1zg5DAjg3ut3qtlhA_KdsCSWQkbwsuf56W_9fxYPzp_FE7iKSmM_7u7vPYRrPIhiSLDpLdhc_F66R-hfLfLHjSAT-H7RmvMXfy82dw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Maintenance+DFMO+Increases+Survival+in+High+Risk+Neuroblastoma&rft.jtitle=Scientific+reports&rft.au=Sholler%2C+Giselle+L+Saulnier&rft.au=Ferguson%2C+William&rft.au=Bergendahl%2C+Genevieve&rft.au=Bond%2C+Jeffrey+P&rft.date=2018-09-27&rft.eissn=2045-2322&rft.volume=8&rft.issue=1&rft.spage=14445&rft_id=info:doi/10.1038%2Fs41598-018-32659-w&rft_id=info%3Apmid%2F30262852&rft.externalDocID=30262852 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |